Search PubMed⌕ Search

Biomedical subjects

J Bonneterre

Publications and source records attributed to J Bonneterre.

At least 163 records · Page 9Linked to original sources
PubMed1984

[Receptors for steroid hormones apart from breast cancer. Practical value].

The steroid receptor (ER, PgR) content of breast cancer specimens is now widely used as an indicator for hormone sensitivity which is a prerequisite for endocrine therapy. Is it conceivable to extend this steroid receptor determination to other types of tumors in order to select patients who would eventually benefit from an hormonal therapy? It seems that most normal or tumoral tissues contain detectable amount of steroid receptors. The values of each receptor comprise a continuum from very low to relatively high, suggesting that previous considerations of hormone dependence on the basis of presence or absence of hormone receptors may be oversimplified. The steroid receptor concentrations are however higher in target tissues, and could be of clinical interest in endometrium and prostatic cancers. The date are however insufficient to draw firm conclusions regarding their usefulness for treatment.

Cervix Uteri↗
PubMed1983

Cis-platinum complex with retained prolactin receptor specific binding.

Two complexes of prolactin and platinum have been synthetized and their biological activity was assayed by radioreceptor assay. Only the cis-platinum prolactin complex retains the capacity of native prolactin to bind to cell receptor membrane. Prolactin could be used to increase the specificity of cis-platinum to cells with prolactin receptors.

Cisplatin↗
PubMed1983

Nuclear estradiol-binding sites in human breast cancer.

The binding of estradiol to nuclear fractions extracted from human breast carcinomatous tissue was demonstrated. The material, which was extracted with KCl, had an approximate molecular weight of 37,000 and bound estradiol with both high and low affinity (Kd congruent to 1 nM, type A receptors; Kd congruent to 30 nM, type B receptors) as calculated according to the method of Scatchard. Competition studies indicated that both components were specific for estradiol, and among the 134 tumors studied the receptors were found to be linked in almost all cases. Thirty-six % of the tumors were nuclear receptor positive. Cytoplasmic estradiol and progesterone receptors were also measured. Among the cytoplasmic tumors positive for cytoplasmic and progesterone receptors, 37% were devoid of both types of nuclear receptors; this may explain the failure of endocrine therapy in some cases. The determination of nuclear binding sites in human breast tumors appeared to be an interesting criterion for the assessment of estradiol-dependent cell growth.

Adenocarcinoma↗
PubMed1982

Prolactin receptors in human breast cancer.

Prolactin receptors have been measured in 92 human breast carcinomas. Both free and total receptors (after desaturation by MgCl2) have been looked for. Free receptors have been found in 46% of the cases, total receptors in 72%. Specific binding ranges from 0.8 to 8.0%. No correlation could be found between prolactin receptors and age, weight, menopausal status and pathological features (differentiation, histoprognostic grading, cellular density). A highly significant correlation has been found between prolactin receptors on the one hand and estradiol and progesterone receptors on the other.

Adenocarcinoma↗
PubMed1982

[Neurologic manifestations of spinal plasmacytomas].

Twenty nine cases of plasmocytic spinal cord tumors which were responsible for neurological troubles were collected over the 19 year period between 1962 and 1981. In 25 of the cases, spinal cord compression was the first sign of the tumor. In 4 of the cases, spinal cord compression was a secondary complication of an already known tumor. The various problems associated with this pathological process are discussed. The neurological problem is fairly straight forward: whether the compression is the first sign of the tumor, and whether it is a secondary complication, it must be surgically removed. Subsequent radiotherapy and chemotherapy are advisable. The oncogenous problem is more delicate. If the plasmocyte is a solitary tumor, and surgical removed is complete, the patient is, in theory, "heated", but should be regularly seen an outpatient basis. On the other hand, a multiple myeloma may first show it self as a spinal cord tumor, where as the patient is in reality suffering from a generalized disease.

Adult↗
PubMed1981

Dihydropteridine-reductase activity in breast cancer. Preliminary report.

The dihydropteridine-reductase activity was measured in 206 breast cancers. Large variations were found: 6% of tumors showing high values closed to those noted in liver, whereas the main group has activities of same magnitude of that in cultured fibroblasts. Significant correlation appeared between dihydropteridine-reductase activities and hormonal dependence, as measured by cytosolic estrogen receptor sites.

Breast Neoplasms↗
PubMedDate not supplied

Subclass restriction of the antiidiotypic antibody response in the rat.

Antiidiotypic antibodies were induced in LOU/M rats by immunization with two myeloma proteins of LOU origin: IR-162 (IgE) and IR-418 (IgG2a). Antibodies to IR-162 were easily obtained after a limited number of immunizations with protein in soluble form; polymerization with glutaraldehyde did not enhance immunogenicity. Antibodies to IR-418 appeared only after a large number of immunizations with protein in polymerized form or with protein copolymerized with rabbit IgG. All of the antibodies, either to IR-162 or to IR-418, were found to be idiotype-specific. In every case for which significant levels of antiidiotypic antibodies were produced, most or all of the antibodies belonged to rat IgG1 subclass. Since, in mice, antiidiotypic antibodies are restricted to the IgG1 subclass, our results indicate a functional analogy between rat and mouse IgG1. Our studies also suggest that the rat IgG1 subclass may be predominantly expressed in T-cell-dependent antibody responses, such as production of antiidiotypic antibodies.

Animals↗
PubMedDate not supplied

Prognostic value of tumoral sialyltransferase expression and circulating E-selectin concentrations in node-negative breast cancer patients.

AIMS AND BACKGROUND: A crucial step in the metastatic process is the interaction between the endothelial molecule E-selectin and its tumoral ligands sialyl-Lewis- and sialyl-Lewis. Sialyltranferases are involved in the biosynthesis of these ligands. The aim of this study was to assess the prognostic value of tumoral sialyltransferase expression and of circulating soluble E-selectin (sE-selectin) in node-negative breast cancer patients. METHODS: Using a multiplex RT-PCR method, we measured the expression of five sialyltransferases (ST3Gal III, ST6Gal I, ST3Gal IV, ST3Gal I and ST3Gal II) in tumors of 135 surgically treated node-negative breast cancer patients. Circulating sE-selectin concentrations were measured by an ELISA method prior to surgery. We also analyzed tumor size, histoprognostic grading and steroid hormone receptor status. RESULTS: The median follow-up was 7.5 years. Expression of estrogen receptors was associated with a good prognosis for relapse-free survival in univariate analysis. A high ST3Gal III/ST6Gal I ratio and a high sE-selectin concentration were associated with a bad prognosis for relapse-free survival and overall survival in univariate and multivariate analysis. CONCLUSION: In the present study, tumoral sialyltransferase expression and circulating sE-selectin concentrations had prognostic value in patients with node-negative breast cancer. This result provides further evidence for the important role of these agents in the metastatic process.

Adult↗
PubMedDate not supplied

[Multicenter prospective study of cardiac accidents during treatments with 5-FU].

In a prospective, multicenter study, we evaluated the incidence of adverse cardiac effects in 1097 patients receiving 5-FU as a short i.v. perfusion or as a continuous perfusion over 3 to 5 days. There were 29 cardiac events (incidence 1.6%; 4.5% in patients with a history of cardiovascular disease, 1.1% in the remainder). Adverse effects were more frequent in the patients with advanced WHO (WHO = OMS) stage (2 or 3) primary tumors of the upper respiratory or digestive tract, or of the gastrointestinal tract, when 5-FU was given as a continuous perfusion. They also appeared to be more frequent in patients with a history of cardiovascular disease, and mainly occurred during the second or third day of the first course of treatment. Retreatment of eight patients with 5-FU led to the recurrence of symptoms in five. The outcome of these adverse cardiac effects was generally favorable, but 11.5% of the patients died.

Fluorouracil↗
PubMedDate not supplied

Plasma acid and alkaline phosphatase in patients with breast cancer.

Acid and alkaline phosphatase were determined in 107 breast cancer patients to study their potential value in case of bone metastases. The patients were divided into 4 groups: A, patients without metastases (n = 34); B, metastatic patients without bone lesions (n = 37); C, patients with metastases in and outside of bones (n = 24), D, patients with bone-only metastases (n = 12). Tartrate resistant acid phosphatase (TR-ACP), and bone alkaline phosphatase (bone-ALP) were significantly higher in patients with metastases than in patients without. However, no difference in TR-ACP was observed between subgroups of metastatic patients.

Acid Phosphatase↗
PubMedDate not supplied

Effect of the long-acting somatostatin analogue SMS 201-995 (Sandostatin) in advanced breast cancer.

Sixteen post-menopausal patients with advanced breast cancer were treated with a long acting somatostatin analogue, SMS 201-995 (Sandostatin): 0.1 mg bid sub-cutaneously. The dose was chosen on the basis of efficiency in acromegaly treatment. SMS 201-995 activity was evaluated assaying Insulin Growth Factor 1 (IGF1) plasma concentration. A merely partial IGF1 decrease was noted. To be evaluable for response, patients had to be treated for at least 30 days. Among the 14 evaluable patients, we observed no response to SMS 201-995. However, we noted tumor stabilization in 3 patients after a 90 days treatment period. Side-effects were very mild. This first report on SMS 201-995 treatment of breast cancer suggests that further studies evaluating the effect of other modes of administration or drug association should be warranted.

Adult↗